Flexion Therapeutics Inc (NASDAQ:FLXN) has earned a consensus recommendation of “Buy” from the seven analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have given a buy recommendation to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $39.00.

Several analysts recently issued reports on the stock. BidaskClub raised shares of Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, August 15th. Zacks Investment Research cut shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, August 13th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Flexion Therapeutics in a report on Monday, November 5th. Finally, ValuEngine cut shares of Flexion Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, September 21st.

Shares of FLXN stock traded up $1.33 on Thursday, hitting $17.55. The stock had a trading volume of 10,658 shares, compared to its average volume of 900,657. The company has a market capitalization of $642.05 million, a PE ratio of -4.22 and a beta of 1.13. The company has a current ratio of 8.88, a quick ratio of 8.74 and a debt-to-equity ratio of 1.02. Flexion Therapeutics has a 52-week low of $13.36 and a 52-week high of $29.10.

Flexion Therapeutics (NASDAQ:FLXN) last announced its earnings results on Wednesday, November 7th. The specialty pharmaceutical company reported ($1.15) earnings per share for the quarter, beating the consensus estimate of ($1.24) by $0.09. The business had revenue of $6.99 million during the quarter, compared to the consensus estimate of $5.93 million. Flexion Therapeutics had a negative net margin of 1,346.87% and a negative return on equity of 88.21%. Equities research analysts predict that Flexion Therapeutics will post -4.68 EPS for the current year.

In other Flexion Therapeutics news, insider Michael D. Clayman bought 5,000 shares of the company’s stock in a transaction on Friday, November 9th. The shares were bought at an average cost of $17.10 per share, with a total value of $85,500.00. Following the completion of the acquisition, the insider now owns 83,295 shares of the company’s stock, valued at $1,424,344.50. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO David Arkowitz bought 4,000 shares of the company’s stock in a transaction on Friday, November 9th. The shares were acquired at an average cost of $16.56 per share, for a total transaction of $66,240.00. Following the completion of the acquisition, the chief financial officer now directly owns 48,250 shares of the company’s stock, valued at approximately $799,020. The disclosure for this purchase can be found here. 14.59% of the stock is currently owned by corporate insiders.

Several large investors have recently modified their holdings of the business. Dimensional Fund Advisors LP acquired a new stake in shares of Flexion Therapeutics during the third quarter worth $895,000. Rubric Capital Management LP raised its holdings in shares of Flexion Therapeutics by 7.7% during the third quarter. Rubric Capital Management LP now owns 2,125,000 shares of the specialty pharmaceutical company’s stock worth $39,759,000 after purchasing an additional 151,286 shares during the period. Pictet Asset Management Ltd. raised its holdings in shares of Flexion Therapeutics by 10.7% during the third quarter. Pictet Asset Management Ltd. now owns 1,362,171 shares of the specialty pharmaceutical company’s stock worth $25,486,000 after purchasing an additional 131,115 shares during the period. BlackRock Inc. raised its holdings in shares of Flexion Therapeutics by 1.4% during the third quarter. BlackRock Inc. now owns 2,868,988 shares of the specialty pharmaceutical company’s stock worth $53,679,000 after purchasing an additional 39,511 shares during the period. Finally, Wasatch Advisors Inc. grew its position in shares of Flexion Therapeutics by 27.8% during the third quarter. Wasatch Advisors Inc. now owns 828,224 shares of the specialty pharmaceutical company’s stock worth $15,496,000 after acquiring an additional 180,293 shares during the last quarter. 98.38% of the stock is currently owned by institutional investors.

Flexion Therapeutics Company Profile

Flexion Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes Zilretta, an intra-articular injection for the management of osteoarthritis (OA) pain of the knee.

Featured Article: Is the Dow Jones Industrial Average (DJIA) still relevant?

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.